Company intelligence / Profile preview

NYAEMP

Basel, Basel-Stadt, Switzerlandnyaemp.org ↗

Ownership: Private
Development stage: Other

Overview

Noema Pharma is advancing four clinical-stage assets for neuroscience-based conditions with high unmet need. All lead programs are in Phase 2 trials, targeting severe CNS disorders such as trigeminal neuralgia, tuberous sclerosis complex (seizures), Tourette syndrome, and vasomotor/CNS-mediated menopausal symptoms. Clinical readouts are expected in 2025. The company has raised significant venture capital to support these efforts and is recognized for its strong management team and investor syndicate.

Therapeutic areas: PsychiatryNeurologyWomen's Health
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on NYAEMP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NYAEMP.

Explore the full profile